TP53 or Not TP53: That Is the Question

被引：0
|
作者：
Green, Steven D. [1 ]
Zeidner, Joshua F. [2 ,3 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Med, Div Hematol, 170 Manning Dr,Houpt Bldg,CB7305, Chapel Hill, NC 27599 USA
来源：
CLINICAL CANCER RESEARCH | 2022年 / 28卷 / 24期
关键词：
ACUTE MYELOID-LEUKEMIA; CLASSIFICATION; VALIDATION;
D O I：
10.1158/1078-0432.CCR-22-2664
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens.
引用
收藏
页码：5235 / 5237
页数：3
相关论文
共 50 条
  • [1] The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
    Leroy, Bernard
    Fournier, Jean Louis
    Ishioka, Chikashi
    Monti, Paola
    Inga, Alberto
    Fronza, Gilberto
    Soussi, Thierry
    NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D962 - D969
  • [2] TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy
    Hu, Wanglai
    Chen, Song
    Thorne, Rick F.
    Wu, Mian
    AUTOPHAGY: BIOLOGY AND DISEASES: BASIC SCIENCE, 2019, 1206 : 127 - 149
  • [3] Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
    Tesio, Melania
    HEMASPHERE, 2023, 7 (02):
  • [4] TP53 Action and the Consequences of TP53 Mutation in Acute Myeloid Leukemia
    Lowe, Scott W.
    BLOOD, 2019, 134
  • [5] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
    Valk, Peter J. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
  • [6] Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway
    Saba, Karim H.
    Difilippo, Valeria
    Kovac, Michal
    Cornmark, Louise
    Magnusson, Linda
    Nilsson, Jenny
    van den Bos, Hilda
    Spierings, Diana C. J.
    Bidgoli, Mahtab
    Jonson, Tord
    Sumathi, Vaiyapuri P.
    Brosjoe, Otte
    Staaf, Johan
    Foijer, Floris
    Styring, Emelie
    Nathrath, Michaela
    Baumhoer, Daniel
    Nord, Karolin H.
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 147 - 160
  • [7] Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone
    Ohnishi, T
    Ohnishi, K
    Wang, XJ
    Takahashi, A
    Okaichi, K
    RADIATION RESEARCH, 1999, 151 (04) : 498 - 500
  • [8] Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
    Trauernicht, Max
    Rastogi, Chaitanya
    Manzo, Stefano G.
    Bussemaker, Harmen J.
    van Steensel, Bas
    NUCLEIC ACIDS RESEARCH, 2023, 51 (18) : 9690 - 9702
  • [9] Sarcomas in TP53 Germline Mutation Carriers A Review of the IARC TP53 Database
    Ognjanovic, Simona
    Olivier, Magali
    Bergemann, Tracy L.
    Hainaut, Pierre
    CANCER, 2012, 118 (05) : 1387 - 1396
  • [10] TP53 and ovarian cancer
    Schuijer, M
    Berns, EMJJ
    HUMAN MUTATION, 2003, 21 (03) : 285 - 291
12345